121 related articles for article (PubMed ID: 32334110)
21. MEK inhibitors for the treatment of NRAS mutant melanoma.
Sarkisian S; Davar D
Drug Des Devel Ther; 2018; 12():2553-2565. PubMed ID: 30154648
[TBL] [Abstract][Full Text] [Related]
22. Neural crest state activation in NRAS driven melanoma, but not in NRAS-driven melanocyte expansion.
McConnell AM; Mito JK; Ablain J; Dang M; Formichella L; Fisher DE; Zon LI
Dev Biol; 2019 May; 449(2):107-114. PubMed ID: 29883661
[TBL] [Abstract][Full Text] [Related]
23. Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma.
Reyes-Uribe P; Adrianzen-Ruesta MP; Deng Z; Echevarria-Vargas I; Mender I; Saheb S; Liu Q; Altieri DC; Murphy ME; Shay JW; Lieberman PM; Villanueva J
Oncogene; 2018 Jul; 37(30):4058-4072. PubMed ID: 29695835
[TBL] [Abstract][Full Text] [Related]
24. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients.
Kirchberger MC; Ugurel S; Mangana J; Heppt MV; Eigentler TK; Berking C; Schadendorf D; Schuler G; Dummer R; Heinzerling L
Eur J Cancer; 2018 Jul; 98():10-16. PubMed ID: 29843107
[TBL] [Abstract][Full Text] [Related]
25. Increased levels of β-catenin, LEF-1, and HPA-1 correlate with poor prognosis for acral melanoma with negative BRAF and NRAS mutation in BRAF exons 11 and 15 and NRAS exons 1 and 2.
Xu S; Yang Z; Zhang J; Jiang Y; Chen Y; Li H; Liu X; Xu D; Chen Y; Yang Y; Zhang Y; Li D; Xia J
DNA Cell Biol; 2015 Jan; 34(1):69-77. PubMed ID: 25343173
[TBL] [Abstract][Full Text] [Related]
26. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma.
Suarez-Kelly LP; Kemper GM; Duggan MC; Stiff A; Noel TC; Markowitz J; Luedke EA; Yildiz VO; Yu L; Jaime-Ramirez AC; Karpa V; Zhang X; Carson WE
Oncotarget; 2016 Dec; 7(49):81172-81186. PubMed ID: 27783987
[TBL] [Abstract][Full Text] [Related]
27. 17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAF
Mielczarek-Lewandowska A; Sztiller-Sikorska M; Osrodek M; Czyz M; Hartman ML
Apoptosis; 2019 Aug; 24(7-8):596-611. PubMed ID: 30989459
[TBL] [Abstract][Full Text] [Related]
28. Protein kinase Cδ is a therapeutic target in malignant melanoma with NRAS mutation.
Takashima A; English B; Chen Z; Cao J; Cui R; Williams RM; Faller DV
ACS Chem Biol; 2014 Apr; 9(4):1003-14. PubMed ID: 24506253
[TBL] [Abstract][Full Text] [Related]
29. MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma.
Vu HL; Rosenbaum S; Capparelli C; Purwin TJ; Davies MA; Berger AC; Aplin AE
J Invest Dermatol; 2016 Feb; 136(2):453-463. PubMed ID: 26967478
[TBL] [Abstract][Full Text] [Related]
30. Magnolol induces cell death through PI3K/Akt-mediated epigenetic modifications boosting treatment of BRAF- and NRAS-mutant melanoma.
Emran AA; Chinna Chowdary BR; Ahmed F; Hammerlindl H; Huefner A; Haass NK; Schuehly W; Schaider H
Cancer Med; 2019 Mar; 8(3):1186-1196. PubMed ID: 30793515
[TBL] [Abstract][Full Text] [Related]
31. Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.
Atefi M; Titz B; Avramis E; Ng C; Wong DJ; Lassen A; Cerniglia M; Escuin-Ordinas H; Foulad D; Comin-Anduix B; Graeber TG; Ribas A
Mol Cancer; 2015 Feb; 14(1):27. PubMed ID: 25645078
[TBL] [Abstract][Full Text] [Related]
32. Targeting NRAS-Mutant Cancers with the Selective STK19 Kinase Inhibitor Chelidonine.
Qian L; Chen K; Wang C; Chen Z; Meng Z; Wang P
Clin Cancer Res; 2020 Jul; 26(13):3408-3419. PubMed ID: 32156748
[TBL] [Abstract][Full Text] [Related]
33. The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells.
Lin R; Xia S; Shan C; Chen D; Liu Y; Gao X; Wang M; Kang HB; Pan Y; Liu S; Chung YR; Abdel-Wahab O; Merghoub T; Rossi M; Kudchadkar RR; Lawson DH; Khuri FR; Lonial S; Chen J
Mol Cell; 2018 Mar; 69(6):923-937.e8. PubMed ID: 29547721
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C
BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232
[TBL] [Abstract][Full Text] [Related]
35. Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.
Vujic I; Sanlorenzo M; Posch C; Esteve-Puig R; Yen AJ; Kwong A; Tsumura A; Murphy R; Rappersberger K; Ortiz-Urda S
Oncotarget; 2015 Jan; 6(2):969-78. PubMed ID: 25504439
[TBL] [Abstract][Full Text] [Related]
36. Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells.
Posch C; Sanlorenzo M; Vujic I; Oses-Prieto JA; Cholewa BD; Kim ST; Ma J; Lai K; Zekhtser M; Esteve-Puig R; Green G; Chand S; Burlingame AL; Panzer-Grümayer R; Rappersberger K; Ortiz-Urda S
J Invest Dermatol; 2016 Oct; 136(10):2041-2048. PubMed ID: 27251789
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.
Moltara ME; Novakovic S; Boc M; Bucic M; Rebersek M; Zadnik V; Ocvirk J
Radiol Oncol; 2018 Apr; 52(3):289-295. PubMed ID: 30210039
[TBL] [Abstract][Full Text] [Related]
38. Isothiouronium salts reduce NRAS expression, induce apoptosis and decrease invasion of melanoma cells.
Cisilotto J; Ferreira M; Filippin-Monteiro FB; Bortoluzzi AJ; Sa MM; Creczynski-Pasa TB
Anticancer Agents Med Chem; 2015; 15(3):353-62. PubMed ID: 25469513
[TBL] [Abstract][Full Text] [Related]
39. Concordance of somatic mutational profile in multiple primary melanomas.
Adler NR; McLean CA; Wolfe R; Kelly JW; McArthur GA; Haydon A; Tra T; Cummings N; Mar VJ
Pigment Cell Melanoma Res; 2018 Sep; 31(5):592-603. PubMed ID: 29603877
[TBL] [Abstract][Full Text] [Related]
40. BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study.
Frank GA; Aleksakhina SN; Zavalishina LE; Kekeyeva TV; Venina AR; Ivantsov AO; Mitiushkina NV; Moiseyenko AV; Pfeifer W; Strelkova TN; Imyanitov EN
Melanoma Res; 2016 Oct; 26(5):442-7. PubMed ID: 27433783
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
